nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Estramustine—prostate cancer	0.56	1	CiPCiCtD
Temozolomide—CYP3A4—prostate cancer	0.134	1	CbGaD
Temozolomide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0393	0.207	CbGbCtD
Temozolomide—CYP3A4—Bicalutamide—prostate cancer	0.0206	0.109	CbGbCtD
Temozolomide—CYP3A4—Estramustine—prostate cancer	0.0192	0.101	CbGbCtD
Temozolomide—CYP3A4—Abiraterone—prostate cancer	0.0171	0.09	CbGbCtD
Temozolomide—CYP3A4—Flutamide—prostate cancer	0.0171	0.09	CbGbCtD
Temozolomide—CYP3A4—Cabazitaxel—prostate cancer	0.0127	0.0666	CbGbCtD
Temozolomide—CYP3A4—Estrone—prostate cancer	0.0124	0.0651	CbGbCtD
Temozolomide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.011	0.058	CbGbCtD
Temozolomide—CYP3A4—Conjugated Estrogens—prostate cancer	0.00809	0.0426	CbGbCtD
Temozolomide—CYP3A4—Mitoxantrone—prostate cancer	0.00736	0.0387	CbGbCtD
Temozolomide—CYP3A4—Estradiol—prostate cancer	0.0071	0.0374	CbGbCtD
Temozolomide—CYP3A4—Prednisone—prostate cancer	0.00611	0.0321	CbGbCtD
Temozolomide—CYP3A4—Etoposide—prostate cancer	0.00464	0.0244	CbGbCtD
Temozolomide—CYP3A4—Docetaxel—prostate cancer	0.00424	0.0223	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—prostate cancer	0.00316	0.0166	CbGbCtD
Temozolomide—CYP3A4—Farnesoid X Receptor  Pathway—SULT2A1—prostate cancer	0.00011	0.0101	CbGpPWpGaD
Temozolomide—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—prostate cancer	0.000108	0.00995	CbGpPWpGaD
Temozolomide—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—prostate cancer	0.000105	0.00963	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—SULT2A1—prostate cancer	0.000101	0.00931	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP3A5—prostate cancer	9.88e-05	0.00908	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP2C19—prostate cancer	9.39e-05	0.00862	CbGpPWpGaD
Temozolomide—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—prostate cancer	9.2e-05	0.00846	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP2A6—prostate cancer	9.06e-05	0.00832	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP2C19—prostate cancer	9.03e-05	0.00829	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A43—prostate cancer	8.95e-05	0.00823	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP3A43—prostate cancer	8.84e-05	0.00812	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTCD—prostate cancer	8.74e-05	0.00803	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTK1—prostate cancer	8.74e-05	0.00803	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP2A6—prostate cancer	8.71e-05	0.008	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP7B1—prostate cancer	8.61e-05	0.00791	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—prostate cancer	8.5e-05	0.00781	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—prostate cancer	8.4e-05	0.00772	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—NQO1—prostate cancer	8.28e-05	0.00761	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—prostate cancer	8e-05	0.00735	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—CYP1B1—prostate cancer	7.94e-05	0.0073	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP2E1—prostate cancer	7.7e-05	0.00707	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP2E1—prostate cancer	7.41e-05	0.0068	CbGpPWpGaD
Temozolomide—CYP3A4—Aflatoxin activation and detoxification—GGT1—prostate cancer	7.37e-05	0.00677	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A43—prostate cancer	7.26e-05	0.00667	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	7.23e-05	0.00664	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	7.02e-05	0.00645	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	6.96e-05	0.0064	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—COMT—prostate cancer	6.94e-05	0.00638	CbGpPWpGaD
Temozolomide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	6.9e-05	0.00634	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	6.87e-05	0.00631	CbGpPWpGaD
Temozolomide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	6.83e-05	0.00628	CbGpPWpGaD
Temozolomide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	6.61e-05	0.00608	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	6.44e-05	0.00592	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	6.35e-05	0.00583	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	6.22e-05	0.00571	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	6.02e-05	0.00553	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	5.97e-05	0.00549	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	5.9e-05	0.00542	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	5.82e-05	0.00535	CbGpPWpGaD
Temozolomide—CYP3A4—Irinotecan Pathway—APC—prostate cancer	5.76e-05	0.0053	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	5.67e-05	0.00521	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	5.65e-05	0.00519	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	5.53e-05	0.00508	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	5.32e-05	0.00489	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	5.28e-05	0.00485	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	5.04e-05	0.00463	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	4.84e-05	0.00445	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	4.78e-05	0.00439	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	4.7e-05	0.00432	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	4.64e-05	0.00427	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	4.55e-05	0.00418	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	4.33e-05	0.00397	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	4.33e-05	0.00397	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	4.28e-05	0.00393	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	4.27e-05	0.00392	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTM3—prostate cancer	4.07e-05	0.00374	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	4.07e-05	0.00374	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	4.01e-05	0.00369	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	4.01e-05	0.00369	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	3.95e-05	0.00363	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	3.92e-05	0.00361	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	3.9e-05	0.00358	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	3.86e-05	0.00354	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—NAT1—prostate cancer	3.86e-05	0.00354	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	3.85e-05	0.00353	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	3.81e-05	0.0035	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	3.8e-05	0.00349	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	3.76e-05	0.00346	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	3.75e-05	0.00344	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	3.71e-05	0.00341	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	3.6e-05	0.00331	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	3.55e-05	0.00327	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	3.52e-05	0.00324	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	3.43e-05	0.00315	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	3.31e-05	0.00304	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	3.23e-05	0.00297	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	3.2e-05	0.00294	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	3.16e-05	0.0029	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	3.16e-05	0.0029	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	3.05e-05	0.0028	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	3.03e-05	0.00278	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	3e-05	0.00276	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	2.99e-05	0.00275	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	2.96e-05	0.00272	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	2.92e-05	0.00268	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	2.92e-05	0.00268	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	2.89e-05	0.00266	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	2.88e-05	0.00265	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	2.85e-05	0.00262	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	2.84e-05	0.00261	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	2.81e-05	0.00258	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	2.78e-05	0.00256	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	2.75e-05	0.00253	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	2.59e-05	0.00238	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	2.57e-05	0.00236	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	2.54e-05	0.00233	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA3—prostate cancer	2.48e-05	0.00228	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	2.46e-05	0.00226	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	2.45e-05	0.00225	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	2.34e-05	0.00215	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	2.31e-05	0.00212	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	2.3e-05	0.00211	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA4—prostate cancer	2.27e-05	0.00209	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	2.27e-05	0.00209	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	2.27e-05	0.00208	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	2.24e-05	0.00206	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	2.23e-05	0.00205	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA2—prostate cancer	2.21e-05	0.00203	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	2.19e-05	0.00201	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	2.16e-05	0.00198	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA1—prostate cancer	2.14e-05	0.00196	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTO1—prostate cancer	2.11e-05	0.00194	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—NAT2—prostate cancer	2.11e-05	0.00194	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	2.08e-05	0.00191	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	2.08e-05	0.00191	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	2.03e-05	0.00186	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	2e-05	0.00184	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	1.88e-05	0.00173	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	1.86e-05	0.00171	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	1.86e-05	0.00171	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	1.77e-05	0.00163	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	1.75e-05	0.00161	CbGpPWpGaD
Temozolomide—Hepatobiliary disease—Doxorubicin—prostate cancer	1.69e-05	0.000162	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—HPGDS—prostate cancer	1.69e-05	0.00155	CbGpPWpGaD
Temozolomide—Anorexia—Capecitabine—prostate cancer	1.69e-05	0.000162	CcSEcCtD
Temozolomide—Nausea—Estradiol—prostate cancer	1.69e-05	0.000162	CcSEcCtD
Temozolomide—Vomiting—Mitoxantrone—prostate cancer	1.68e-05	0.000161	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—prostate cancer	1.68e-05	0.000161	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	1.68e-05	0.00154	CbGpPWpGaD
Temozolomide—Convulsion—Prednisone—prostate cancer	1.67e-05	0.000161	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—prostate cancer	1.67e-05	0.000161	CcSEcCtD
Temozolomide—Hypertension—Prednisone—prostate cancer	1.67e-05	0.00016	CcSEcCtD
Temozolomide—Rash—Mitoxantrone—prostate cancer	1.67e-05	0.00016	CcSEcCtD
Temozolomide—Dermatitis—Mitoxantrone—prostate cancer	1.67e-05	0.00016	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Docetaxel—prostate cancer	1.67e-05	0.00016	CcSEcCtD
Temozolomide—Headache—Mitoxantrone—prostate cancer	1.66e-05	0.000159	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	1.66e-05	0.00152	CbGpPWpGaD
Temozolomide—Insomnia—Docetaxel—prostate cancer	1.65e-05	0.000159	CcSEcCtD
Temozolomide—Arthralgia—Prednisone—prostate cancer	1.65e-05	0.000158	CcSEcCtD
Temozolomide—Myalgia—Prednisone—prostate cancer	1.65e-05	0.000158	CcSEcCtD
Temozolomide—Paraesthesia—Docetaxel—prostate cancer	1.64e-05	0.000158	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—prostate cancer	1.64e-05	0.000158	CcSEcCtD
Temozolomide—Anxiety—Prednisone—prostate cancer	1.64e-05	0.000157	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—GSTT1—prostate cancer	1.64e-05	0.00151	CbGpPWpGaD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.63e-05	0.000157	CcSEcCtD
Temozolomide—Dyspnoea—Docetaxel—prostate cancer	1.63e-05	0.000157	CcSEcCtD
Temozolomide—Somnolence—Docetaxel—prostate cancer	1.63e-05	0.000156	CcSEcCtD
Temozolomide—Discomfort—Prednisone—prostate cancer	1.63e-05	0.000156	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—prostate cancer	1.62e-05	0.000156	CcSEcCtD
Temozolomide—Hypersensitivity—Etoposide—prostate cancer	1.62e-05	0.000156	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	1.62e-05	0.00149	CbGpPWpGaD
Temozolomide—Tinnitus—Epirubicin—prostate cancer	1.62e-05	0.000155	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—prostate cancer	1.61e-05	0.000155	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.61e-05	0.000155	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—prostate cancer	1.61e-05	0.000155	CcSEcCtD
Temozolomide—Flushing—Epirubicin—prostate cancer	1.61e-05	0.000155	CcSEcCtD
Temozolomide—Dyspepsia—Docetaxel—prostate cancer	1.61e-05	0.000155	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—prostate cancer	1.61e-05	0.000154	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—prostate cancer	1.61e-05	0.000154	CcSEcCtD
Temozolomide—Insomnia—Capecitabine—prostate cancer	1.6e-05	0.000154	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—prostate cancer	1.6e-05	0.000153	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—prostate cancer	1.59e-05	0.000153	CcSEcCtD
Temozolomide—Paraesthesia—Capecitabine—prostate cancer	1.59e-05	0.000153	CcSEcCtD
Temozolomide—Decreased appetite—Docetaxel—prostate cancer	1.59e-05	0.000153	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—prostate cancer	1.59e-05	0.000152	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—prostate cancer	1.58e-05	0.000152	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Docetaxel—prostate cancer	1.58e-05	0.000152	CcSEcCtD
Temozolomide—Asthenia—Etoposide—prostate cancer	1.58e-05	0.000152	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—prostate cancer	1.58e-05	0.000152	CcSEcCtD
Temozolomide—Dyspnoea—Capecitabine—prostate cancer	1.58e-05	0.000152	CcSEcCtD
Temozolomide—Oedema—Prednisone—prostate cancer	1.58e-05	0.000151	CcSEcCtD
Temozolomide—Anaphylactic shock—Prednisone—prostate cancer	1.58e-05	0.000151	CcSEcCtD
Temozolomide—Fatigue—Docetaxel—prostate cancer	1.58e-05	0.000151	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—prostate cancer	1.58e-05	0.000151	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—prostate cancer	1.57e-05	0.000151	CcSEcCtD
Temozolomide—Nausea—Mitoxantrone—prostate cancer	1.57e-05	0.000151	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—prostate cancer	1.57e-05	0.000151	CcSEcCtD
Temozolomide—Infection—Prednisone—prostate cancer	1.57e-05	0.00015	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—prostate cancer	1.56e-05	0.00015	CcSEcCtD
Temozolomide—Pain—Docetaxel—prostate cancer	1.56e-05	0.00015	CcSEcCtD
Temozolomide—Constipation—Docetaxel—prostate cancer	1.56e-05	0.00015	CcSEcCtD
Temozolomide—Dyspepsia—Capecitabine—prostate cancer	1.56e-05	0.00015	CcSEcCtD
Temozolomide—Chills—Epirubicin—prostate cancer	1.56e-05	0.00015	CcSEcCtD
Temozolomide—Pruritus—Etoposide—prostate cancer	1.56e-05	0.000149	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	1.55e-05	0.00143	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	1.55e-05	0.00142	CbGpPWpGaD
Temozolomide—Visual impairment—Doxorubicin—prostate cancer	1.55e-05	0.000149	CcSEcCtD
Temozolomide—Nervous system disorder—Prednisone—prostate cancer	1.55e-05	0.000148	CcSEcCtD
Temozolomide—Decreased appetite—Capecitabine—prostate cancer	1.54e-05	0.000148	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—prostate cancer	1.53e-05	0.000147	CcSEcCtD
Temozolomide—Skin disorder—Prednisone—prostate cancer	1.53e-05	0.000147	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	1.53e-05	0.00141	CbGpPWpGaD
Temozolomide—Gastrointestinal disorder—Capecitabine—prostate cancer	1.53e-05	0.000147	CcSEcCtD
Temozolomide—Fatigue—Capecitabine—prostate cancer	1.53e-05	0.000147	CcSEcCtD
Temozolomide—Hyperhidrosis—Prednisone—prostate cancer	1.52e-05	0.000146	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—prostate cancer	1.52e-05	0.000146	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—prostate cancer	1.52e-05	0.000146	CcSEcCtD
Temozolomide—Constipation—Capecitabine—prostate cancer	1.51e-05	0.000145	CcSEcCtD
Temozolomide—Pain—Capecitabine—prostate cancer	1.51e-05	0.000145	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—prostate cancer	1.51e-05	0.000145	CcSEcCtD
Temozolomide—Erythema—Epirubicin—prostate cancer	1.51e-05	0.000145	CcSEcCtD
Temozolomide—Feeling abnormal—Docetaxel—prostate cancer	1.51e-05	0.000145	CcSEcCtD
Temozolomide—Diarrhoea—Etoposide—prostate cancer	1.51e-05	0.000145	CcSEcCtD
Temozolomide—Anorexia—Prednisone—prostate cancer	1.5e-05	0.000144	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—prostate cancer	1.5e-05	0.000144	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—prostate cancer	1.5e-05	0.000144	CcSEcCtD
Temozolomide—Gastrointestinal pain—Docetaxel—prostate cancer	1.5e-05	0.000144	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—prostate cancer	1.49e-05	0.000143	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—prostate cancer	1.49e-05	0.000143	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—prostate cancer	1.48e-05	0.000142	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—NCOA2—prostate cancer	1.48e-05	0.00136	CbGpPWpGaD
Temozolomide—Back pain—Epirubicin—prostate cancer	1.46e-05	0.00014	CcSEcCtD
Temozolomide—Feeling abnormal—Capecitabine—prostate cancer	1.46e-05	0.00014	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—prostate cancer	1.46e-05	0.00014	CcSEcCtD
Temozolomide—Dizziness—Etoposide—prostate cancer	1.45e-05	0.00014	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—prostate cancer	1.45e-05	0.000139	CcSEcCtD
Temozolomide—Gastrointestinal pain—Capecitabine—prostate cancer	1.45e-05	0.000139	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—prostate cancer	1.45e-05	0.000139	CcSEcCtD
Temozolomide—Body temperature increased—Docetaxel—prostate cancer	1.45e-05	0.000139	CcSEcCtD
Temozolomide—Abdominal pain—Docetaxel—prostate cancer	1.45e-05	0.000139	CcSEcCtD
Temozolomide—Chills—Doxorubicin—prostate cancer	1.44e-05	0.000138	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Prednisone—prostate cancer	1.44e-05	0.000138	CcSEcCtD
Temozolomide—Insomnia—Prednisone—prostate cancer	1.43e-05	0.000137	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—prostate cancer	1.42e-05	0.000137	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—prostate cancer	1.42e-05	0.000136	CcSEcCtD
Temozolomide—Paraesthesia—Prednisone—prostate cancer	1.42e-05	0.000136	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—prostate cancer	1.41e-05	0.000135	CcSEcCtD
Temozolomide—Urticaria—Capecitabine—prostate cancer	1.41e-05	0.000135	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—prostate cancer	1.4e-05	0.000135	CcSEcCtD
Temozolomide—Abdominal pain—Capecitabine—prostate cancer	1.4e-05	0.000134	CcSEcCtD
Temozolomide—Body temperature increased—Capecitabine—prostate cancer	1.4e-05	0.000134	CcSEcCtD
Temozolomide—Vomiting—Etoposide—prostate cancer	1.4e-05	0.000134	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—prostate cancer	1.4e-05	0.000134	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—prostate cancer	1.4e-05	0.000134	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—prostate cancer	1.4e-05	0.000134	CcSEcCtD
Temozolomide—Agitation—Epirubicin—prostate cancer	1.39e-05	0.000133	CcSEcCtD
Temozolomide—Dyspepsia—Prednisone—prostate cancer	1.39e-05	0.000133	CcSEcCtD
Temozolomide—Rash—Etoposide—prostate cancer	1.39e-05	0.000133	CcSEcCtD
Temozolomide—Dermatitis—Etoposide—prostate cancer	1.39e-05	0.000133	CcSEcCtD
Temozolomide—Headache—Etoposide—prostate cancer	1.38e-05	0.000132	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	1.38e-05	0.00127	CbGpPWpGaD
Temozolomide—Decreased appetite—Prednisone—prostate cancer	1.37e-05	0.000132	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—prostate cancer	1.37e-05	0.000131	CcSEcCtD
Temozolomide—Malaise—Epirubicin—prostate cancer	1.36e-05	0.000131	CcSEcCtD
Temozolomide—Fatigue—Prednisone—prostate cancer	1.36e-05	0.000131	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	1.36e-05	0.00125	CbGpPWpGaD
Temozolomide—Vertigo—Epirubicin—prostate cancer	1.36e-05	0.00013	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—prostate cancer	1.35e-05	0.00013	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—prostate cancer	1.35e-05	0.00013	CcSEcCtD
Temozolomide—Constipation—Prednisone—prostate cancer	1.35e-05	0.000129	CcSEcCtD
Temozolomide—Hypersensitivity—Docetaxel—prostate cancer	1.35e-05	0.000129	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—prostate cancer	1.34e-05	0.000128	CcSEcCtD
Temozolomide—Cough—Epirubicin—prostate cancer	1.32e-05	0.000127	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—prostate cancer	1.32e-05	0.000127	CcSEcCtD
Temozolomide—Asthenia—Docetaxel—prostate cancer	1.31e-05	0.000126	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—prostate cancer	1.31e-05	0.000126	CcSEcCtD
Temozolomide—Nausea—Etoposide—prostate cancer	1.31e-05	0.000125	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	1.31e-05	0.0012	CbGpPWpGaD
Temozolomide—Hypertension—Epirubicin—prostate cancer	1.3e-05	0.000125	CcSEcCtD
Temozolomide—Hypersensitivity—Capecitabine—prostate cancer	1.3e-05	0.000125	CcSEcCtD
Temozolomide—Feeling abnormal—Prednisone—prostate cancer	1.3e-05	0.000125	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—prostate cancer	1.3e-05	0.000125	CcSEcCtD
Temozolomide—Pruritus—Docetaxel—prostate cancer	1.29e-05	0.000124	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—prostate cancer	1.29e-05	0.000124	CcSEcCtD
Temozolomide—Gastrointestinal pain—Prednisone—prostate cancer	1.29e-05	0.000124	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	1.29e-05	0.00118	CbGpPWpGaD
Temozolomide—Arthralgia—Epirubicin—prostate cancer	1.29e-05	0.000124	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—prostate cancer	1.29e-05	0.000124	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—prostate cancer	1.28e-05	0.000123	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—prostate cancer	1.28e-05	0.000123	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.28e-05	0.000123	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—prostate cancer	1.27e-05	0.000122	CcSEcCtD
Temozolomide—Asthenia—Capecitabine—prostate cancer	1.27e-05	0.000122	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—GGT1—prostate cancer	1.26e-05	0.00116	CbGpPWpGaD
Temozolomide—Malaise—Doxorubicin—prostate cancer	1.26e-05	0.000121	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—prostate cancer	1.26e-05	0.000121	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—prostate cancer	1.26e-05	0.000121	CcSEcCtD
Temozolomide—Urticaria—Prednisone—prostate cancer	1.25e-05	0.00012	CcSEcCtD
Temozolomide—Pruritus—Capecitabine—prostate cancer	1.25e-05	0.00012	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—prostate cancer	1.25e-05	0.00012	CcSEcCtD
Temozolomide—Diarrhoea—Docetaxel—prostate cancer	1.25e-05	0.00012	CcSEcCtD
Temozolomide—Body temperature increased—Prednisone—prostate cancer	1.25e-05	0.00012	CcSEcCtD
Temozolomide—Abdominal pain—Prednisone—prostate cancer	1.25e-05	0.00012	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—NCOA1—prostate cancer	1.25e-05	0.00114	CbGpPWpGaD
Temozolomide—Confusional state—Epirubicin—prostate cancer	1.24e-05	0.000119	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—prostate cancer	1.24e-05	0.000119	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—prostate cancer	1.23e-05	0.000118	CcSEcCtD
Temozolomide—Oedema—Epirubicin—prostate cancer	1.23e-05	0.000118	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	1.23e-05	0.00113	CbGpPWpGaD
Temozolomide—Infection—Epirubicin—prostate cancer	1.23e-05	0.000118	CcSEcCtD
Temozolomide—Cough—Doxorubicin—prostate cancer	1.22e-05	0.000117	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—prostate cancer	1.21e-05	0.000116	CcSEcCtD
Temozolomide—Diarrhoea—Capecitabine—prostate cancer	1.21e-05	0.000116	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	1.21e-05	0.00111	CbGpPWpGaD
Temozolomide—Nervous system disorder—Epirubicin—prostate cancer	1.21e-05	0.000116	CcSEcCtD
Temozolomide—Dizziness—Docetaxel—prostate cancer	1.21e-05	0.000116	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—prostate cancer	1.21e-05	0.000116	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—prostate cancer	1.21e-05	0.000116	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—prostate cancer	1.2e-05	0.000115	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—prostate cancer	1.19e-05	0.000114	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—prostate cancer	1.19e-05	0.000114	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—prostate cancer	1.19e-05	0.000114	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—prostate cancer	1.19e-05	0.000114	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—RXRA—prostate cancer	1.18e-05	0.00109	CbGpPWpGaD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.18e-05	0.000113	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—prostate cancer	1.18e-05	0.000113	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—prostate cancer	1.18e-05	0.000113	CcSEcCtD
Temozolomide—Dizziness—Capecitabine—prostate cancer	1.17e-05	0.000112	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—prostate cancer	1.16e-05	0.000112	CcSEcCtD
Temozolomide—Vomiting—Docetaxel—prostate cancer	1.16e-05	0.000112	CcSEcCtD
Temozolomide—Hypersensitivity—Prednisone—prostate cancer	1.16e-05	0.000112	CcSEcCtD
Temozolomide—Rash—Docetaxel—prostate cancer	1.15e-05	0.000111	CcSEcCtD
Temozolomide—Dermatitis—Docetaxel—prostate cancer	1.15e-05	0.000111	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—prostate cancer	1.15e-05	0.00011	CcSEcCtD
Temozolomide—Headache—Docetaxel—prostate cancer	1.15e-05	0.00011	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—prostate cancer	1.14e-05	0.00011	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—prostate cancer	1.14e-05	0.00011	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—COMT—prostate cancer	1.14e-05	0.00105	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTP1—prostate cancer	1.14e-05	0.00104	CbGpPWpGaD
Temozolomide—Infection—Doxorubicin—prostate cancer	1.13e-05	0.000109	CcSEcCtD
Temozolomide—Asthenia—Prednisone—prostate cancer	1.13e-05	0.000109	CcSEcCtD
Temozolomide—Vomiting—Capecitabine—prostate cancer	1.13e-05	0.000108	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	1.13e-05	0.00103	CbGpPWpGaD
Temozolomide—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.12e-05	0.000108	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	1.12e-05	0.00103	CbGpPWpGaD
Temozolomide—Nervous system disorder—Doxorubicin—prostate cancer	1.12e-05	0.000107	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—prostate cancer	1.12e-05	0.000107	CcSEcCtD
Temozolomide—Rash—Capecitabine—prostate cancer	1.12e-05	0.000107	CcSEcCtD
Temozolomide—Pruritus—Prednisone—prostate cancer	1.12e-05	0.000107	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—prostate cancer	1.12e-05	0.000107	CcSEcCtD
Temozolomide—Dermatitis—Capecitabine—prostate cancer	1.12e-05	0.000107	CcSEcCtD
Temozolomide—Headache—Capecitabine—prostate cancer	1.11e-05	0.000106	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—prostate cancer	1.11e-05	0.000106	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—prostate cancer	1.11e-05	0.000106	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—prostate cancer	1.1e-05	0.000106	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—prostate cancer	1.1e-05	0.000106	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—prostate cancer	1.1e-05	0.000105	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—prostate cancer	1.09e-05	0.000104	CcSEcCtD
Temozolomide—Nausea—Docetaxel—prostate cancer	1.09e-05	0.000104	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—prostate cancer	1.09e-05	0.000104	CcSEcCtD
Temozolomide—Diarrhoea—Prednisone—prostate cancer	1.08e-05	0.000104	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—prostate cancer	1.07e-05	0.000103	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—prostate cancer	1.06e-05	0.000102	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—prostate cancer	1.06e-05	0.000102	CcSEcCtD
Temozolomide—Pain—Epirubicin—prostate cancer	1.05e-05	0.000101	CcSEcCtD
Temozolomide—Constipation—Epirubicin—prostate cancer	1.05e-05	0.000101	CcSEcCtD
Temozolomide—Nausea—Capecitabine—prostate cancer	1.05e-05	0.000101	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—GSTM1—prostate cancer	1.04e-05	0.000959	CbGpPWpGaD
Temozolomide—Dizziness—Prednisone—prostate cancer	1.04e-05	0.0001	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.04e-05	9.98e-05	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—prostate cancer	1.03e-05	9.91e-05	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	1.03e-05	0.000946	CbGpPWpGaD
Temozolomide—Paraesthesia—Doxorubicin—prostate cancer	1.02e-05	9.84e-05	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—prostate cancer	1.02e-05	9.77e-05	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—prostate cancer	1.02e-05	9.76e-05	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—prostate cancer	1.01e-05	9.74e-05	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—prostate cancer	1.01e-05	9.68e-05	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—prostate cancer	1e-05	9.64e-05	CcSEcCtD
Temozolomide—Vomiting—Prednisone—prostate cancer	1e-05	9.63e-05	CcSEcCtD
Temozolomide—Rash—Prednisone—prostate cancer	9.94e-06	9.55e-05	CcSEcCtD
Temozolomide—Dermatitis—Prednisone—prostate cancer	9.93e-06	9.54e-05	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—prostate cancer	9.92e-06	9.52e-05	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	9.89e-06	0.000909	CbGpPWpGaD
Temozolomide—Headache—Prednisone—prostate cancer	9.88e-06	9.48e-05	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—prostate cancer	9.85e-06	9.46e-05	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—prostate cancer	9.84e-06	9.45e-05	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—prostate cancer	9.8e-06	9.41e-05	CcSEcCtD
Temozolomide—CYP3A4—Metabolism—HAO1—prostate cancer	9.76e-06	0.000897	CbGpPWpGaD
Temozolomide—Pain—Doxorubicin—prostate cancer	9.76e-06	9.37e-05	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—prostate cancer	9.76e-06	9.37e-05	CcSEcCtD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	9.76e-06	0.000896	CbGpPWpGaD
Temozolomide—Abdominal pain—Epirubicin—prostate cancer	9.75e-06	9.36e-05	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—prostate cancer	9.75e-06	9.36e-05	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—prostate cancer	9.4e-06	9.03e-05	CcSEcCtD
Temozolomide—Nausea—Prednisone—prostate cancer	9.37e-06	8.99e-05	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—prostate cancer	9.33e-06	8.96e-05	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—prostate cancer	9.09e-06	8.72e-05	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—prostate cancer	9.07e-06	8.7e-05	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—prostate cancer	9.02e-06	8.66e-05	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—prostate cancer	9.02e-06	8.66e-05	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—prostate cancer	8.85e-06	8.5e-05	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—prostate cancer	8.73e-06	8.38e-05	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—prostate cancer	8.44e-06	8.1e-05	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—prostate cancer	8.41e-06	8.07e-05	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—prostate cancer	8.19e-06	7.86e-05	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—prostate cancer	8.16e-06	7.83e-05	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—prostate cancer	8.07e-06	7.75e-05	CcSEcCtD
Temozolomide—CYP3A4—Metabolism—TST—prostate cancer	7.96e-06	0.000731	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PSAT1—prostate cancer	7.96e-06	0.000731	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ADI1—prostate cancer	7.96e-06	0.000731	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CBR1—prostate cancer	7.96e-06	0.000731	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GRHL1—prostate cancer	7.96e-06	0.000731	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CSAD—prostate cancer	7.96e-06	0.000731	CbGpPWpGaD
Temozolomide—Vomiting—Epirubicin—prostate cancer	7.84e-06	7.53e-05	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—prostate cancer	7.81e-06	7.5e-05	CcSEcCtD
Temozolomide—Rash—Epirubicin—prostate cancer	7.78e-06	7.47e-05	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—prostate cancer	7.77e-06	7.46e-05	CcSEcCtD
Temozolomide—Headache—Epirubicin—prostate cancer	7.73e-06	7.42e-05	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—prostate cancer	7.55e-06	7.24e-05	CcSEcCtD
Temozolomide—CYP3A4—Metabolism—GRHPR—prostate cancer	7.4e-06	0.00068	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CKMT2—prostate cancer	7.4e-06	0.00068	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—UGT2B15—prostate cancer	7.4e-06	0.00068	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—UGT2B17—prostate cancer	7.4e-06	0.00068	CbGpPWpGaD
Temozolomide—Nausea—Epirubicin—prostate cancer	7.33e-06	7.03e-05	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—prostate cancer	7.26e-06	6.97e-05	CcSEcCtD
Temozolomide—Rash—Doxorubicin—prostate cancer	7.2e-06	6.91e-05	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—prostate cancer	7.19e-06	6.9e-05	CcSEcCtD
Temozolomide—Headache—Doxorubicin—prostate cancer	7.15e-06	6.86e-05	CcSEcCtD
Temozolomide—CYP3A4—Metabolism—NAGLU—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SULT2B1—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—RFK—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—MBTPS1—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTM3—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—AOX1—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PGAM2—prostate cancer	6.96e-06	0.000639	CbGpPWpGaD
Temozolomide—Nausea—Doxorubicin—prostate cancer	6.78e-06	6.51e-05	CcSEcCtD
Temozolomide—CYP3A4—Metabolism—AMACR—prostate cancer	6.59e-06	0.000606	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP3A43—prostate cancer	6.59e-06	0.000606	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NAT1—prostate cancer	6.59e-06	0.000606	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SRD5A2—prostate cancer	6.59e-06	0.000606	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—DEGS1—prostate cancer	6.59e-06	0.000606	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HSD17B1—prostate cancer	6.29e-06	0.000578	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HPGD—prostate cancer	5.61e-06	0.000515	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—B4GALT4—prostate cancer	5.61e-06	0.000515	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—TNFRSF21—prostate cancer	5.27e-06	0.000484	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP7B1—prostate cancer	5.13e-06	0.000471	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—MTAP—prostate cancer	5.13e-06	0.000471	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SULT1E1—prostate cancer	5e-06	0.000459	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SRD5A1—prostate cancer	5e-06	0.000459	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HSD17B3—prostate cancer	4.77e-06	0.000438	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ACSL4—prostate cancer	4.77e-06	0.000438	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PHGDH—prostate cancer	4.57e-06	0.00042	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—UMPS—prostate cancer	4.57e-06	0.00042	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ARG2—prostate cancer	4.57e-06	0.00042	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—LDHB—prostate cancer	4.48e-06	0.000412	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.4e-06	0.000404	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—TCN2—prostate cancer	4.25e-06	0.00039	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—UCP3—prostate cancer	4.25e-06	0.00039	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PDHA1—prostate cancer	4.25e-06	0.00039	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA3—prostate cancer	4.25e-06	0.00039	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.05e-06	0.000372	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.05e-06	0.000372	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.89e-06	0.000357	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA4—prostate cancer	3.89e-06	0.000357	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA2—prostate cancer	3.79e-06	0.000348	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.74e-06	0.000344	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ABCG5—prostate cancer	3.74e-06	0.000344	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA1—prostate cancer	3.65e-06	0.000336	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NAT2—prostate cancer	3.61e-06	0.000332	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.61e-06	0.000332	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTO1—prostate cancer	3.61e-06	0.000332	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PLCB2—prostate cancer	3.46e-06	0.000318	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—LRP2—prostate cancer	3.46e-06	0.000318	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.46e-06	0.000318	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—P4HB—prostate cancer	3.4e-06	0.000312	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.3e-06	0.000304	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.22e-06	0.000296	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—MED12—prostate cancer	3.17e-06	0.000291	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GNG5—prostate cancer	3.14e-06	0.000289	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NCOA3—prostate cancer	3.03e-06	0.000278	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HPGDS—prostate cancer	2.89e-06	0.000265	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.87e-06	0.000264	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTT1—prostate cancer	2.8e-06	0.000257	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ACHE—prostate cancer	2.8e-06	0.000257	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.77e-06	0.000254	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.69e-06	0.000248	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PRKACB—prostate cancer	2.68e-06	0.000246	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.65e-06	0.000244	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NCOA2—prostate cancer	2.53e-06	0.000232	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.41e-06	0.000221	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.35e-06	0.000216	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NQO1—prostate cancer	2.33e-06	0.000214	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—TH—prostate cancer	2.29e-06	0.000211	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.23e-06	0.000205	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GGT1—prostate cancer	2.16e-06	0.000199	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NCOA1—prostate cancer	2.13e-06	0.000196	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.1e-06	0.000193	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—RXRA—prostate cancer	2.03e-06	0.000186	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—COMT—prostate cancer	1.95e-06	0.000179	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTP1—prostate cancer	1.94e-06	0.000178	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ITPR1—prostate cancer	1.91e-06	0.000176	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—TYMS—prostate cancer	1.81e-06	0.000166	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTM1—prostate cancer	1.78e-06	0.000164	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—LPL—prostate cancer	1.75e-06	0.000161	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.69e-06	0.000155	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ERCC2—prostate cancer	1.68e-06	0.000154	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—MTHFR—prostate cancer	1.58e-06	0.000145	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PPARA—prostate cancer	1.55e-06	0.000142	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CAV1—prostate cancer	1.45e-06	0.000134	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.33e-06	0.000122	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—INS—prostate cancer	1.25e-06	0.000115	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CREBBP—prostate cancer	1.23e-06	0.000113	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.16e-06	0.000107	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NOS3—prostate cancer	1.1e-06	0.000101	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.02e-06	9.33e-05	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PTGS2—prostate cancer	1.01e-06	9.24e-05	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PTEN—prostate cancer	8.77e-07	8.06e-05	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—EP300—prostate cancer	8.37e-07	7.69e-05	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.19e-07	5.69e-05	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—AKT1—prostate cancer	5.06e-07	4.65e-05	CbGpPWpGaD
